Skip to content
Research/Hormone Optimization/Estradiol 0.01% Vaginal Cream

Estradiol 0.01% Vaginal Cream

Estradiol 0.01% vaginal cream is a topical hormone therapy used primarily to alleviate symptoms of vaginal atrophy in postmenopausal women. It works by delivering a small dose of estradiol directly to the vaginal tissues, helping to restore moisture and elasticity. This is important for longevity and health optimization as it can improve quality of life and reduce discomfort associated with menopause.

Intelligence Profile

Research Papers

Research on estradiol 0.01% vaginal cream involves several clinical trials exploring its effectiveness in managing various conditions associated with menopause:

  1. Comparison with Estrace® Cream: A completed Phase 3 trial (NCT02195986) studied 350 postmenopausal women with atrophic vaginitis, comparing estradiol vaginal cream with Estrace® cream. This research aimed to evaluate efficacy and safety, though specific outcomes have not been detailed in the available summary.

  2. VEDA Study: Not yet recruiting, this study (NCT07574216) plans to compare DHEA with estradiol in vaginal applications, but further details on design and objectives are limited.

  3. Managing Overactive Bladder Syndrome: An ongoing Phase 4 trial (NCT05221021) is recruiting participants to compare vaginal estradiol with oral beta-3 agonist therapy. This study focuses on overactive bladder syndrome, reflecting interest in the broader applications of estradiol.

  4. Adherence in Recurrent UTIs: Another Phase 4 trial (NCT06353269) is active but no longer recruiting. It investigates adherence to vaginal estrogen therapy among hypoestrogenic women with recurrent urinary tract infections, emphasizing the importance of consistent use in treatment effectiveness.

  5. Genitourinary Syndrome of Menopause: A recruiting trial (NCT05672901) compares silicone gel with estrogen vaginal cream. While specific results are unavailable, it underscores the need for effective management strategies for menopause-associated genitourinary symptoms.

The current evidence surrounding estradiol 0.01% vaginal cream is mainly in-progress, highlighting its potential but requiring more completed research for conclusive results. Always consult healthcare professionals for medical advice.

Disclaimer: This information is for educational purposes and not intended as medical advice. Always seek guidance from healthcare providers for treatment decisions.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.